These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 25453365)
21. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Thaci B; Ahmed AU; Ulasov IV; Wainwright DA; Nigam P; Auffinger B; Tobias AL; Han Y; Zhang L; Moon KS; Lesniak MS Cancer Gene Ther; 2014 Jan; 21(1):38-44. PubMed ID: 24434573 [TBL] [Abstract][Full Text] [Related]
22. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302 [TBL] [Abstract][Full Text] [Related]
23. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Pyzer AR; Cole L; Rosenblatt J; Avigan DE Int J Cancer; 2016 Nov; 139(9):1915-26. PubMed ID: 27299510 [TBL] [Abstract][Full Text] [Related]
24. Origin, activation, and targeted therapy of glioma-associated macrophages. Xu C; Xiao M; Li X; Xin L; Song J; Zhan Q; Wang C; Zhang Q; Yuan X; Tan Y; Fang C Front Immunol; 2022; 13():974996. PubMed ID: 36275720 [TBL] [Abstract][Full Text] [Related]
25. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322 [TBL] [Abstract][Full Text] [Related]
26. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692 [TBL] [Abstract][Full Text] [Related]
27. Exploiting Microglial Functions for the Treatment of Glioblastoma. Dello Russo C; Lisi L; Tentori L; Navarra P; Graziani G; Combs CK Curr Cancer Drug Targets; 2017; 17(3):267-281. PubMed ID: 27528361 [TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Bianchi G; Borgonovo G; Pistoia V; Raffaghello L Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223 [TBL] [Abstract][Full Text] [Related]
29. Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies. Salemizadeh Parizi M; Salemizadeh Parizi F; Abdolhosseini S; Vanaei S; Manzouri A; Ebrahimzadeh F Inflammopharmacology; 2021 Dec; 29(6):1613-1624. PubMed ID: 34613567 [TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. Umemura N; Saio M; Suwa T; Kitoh Y; Bai J; Nonaka K; Ouyang GF; Okada M; Balazs M; Adany R; Shibata T; Takami T J Leukoc Biol; 2008 May; 83(5):1136-44. PubMed ID: 18285406 [TBL] [Abstract][Full Text] [Related]
32. Epithelial-mesenchymal transition is the main way in which glioma-associated microglia/macrophages promote glioma progression. He X; Guo Y; Yu C; Zhang H; Wang S Front Immunol; 2023; 14():1097880. PubMed ID: 36969175 [TBL] [Abstract][Full Text] [Related]
33. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. Sielska M; Przanowski P; Wylot B; Gabrusiewicz K; Maleszewska M; Kijewska M; Zawadzka M; Kucharska J; Vinnakota K; Kettenmann H; Kotulska K; Grajkowska W; Kaminska B J Pathol; 2013 Jul; 230(3):310-21. PubMed ID: 23520016 [TBL] [Abstract][Full Text] [Related]
34. The controversial role of microglia in malignant gliomas. Wei J; Gabrusiewicz K; Heimberger A Clin Dev Immunol; 2013; 2013():285246. PubMed ID: 23983766 [TBL] [Abstract][Full Text] [Related]
35. The Role of Myeloid Cells in GBM Immunosuppression. Lin YJ; Wu CY; Wu JY; Lim M Front Immunol; 2022; 13():887781. PubMed ID: 35711434 [TBL] [Abstract][Full Text] [Related]
36. New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk. Zhao AM; Xu HJ; Kang XM; Zhao AM; Lu LM J Reprod Immunol; 2016 Feb; 113():35-41. PubMed ID: 26599285 [TBL] [Abstract][Full Text] [Related]
37. MDSCs in cancer: Conceiving new prognostic and therapeutic targets. De Sanctis F; Solito S; Ugel S; Molon B; Bronte V; Marigo I Biochim Biophys Acta; 2016 Jan; 1865(1):35-48. PubMed ID: 26255541 [TBL] [Abstract][Full Text] [Related]
38. Cytokine therapy. Ohno M; Natsume A; Wakabayashi T Adv Exp Med Biol; 2012; 746():86-94. PubMed ID: 22639161 [TBL] [Abstract][Full Text] [Related]
40. Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors. Ding AS; Routkevitch D; Jackson C; Lim M Front Immunol; 2019; 10():1715. PubMed ID: 31396227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]